News for EyePoint Pharmaceuticals Stock (EYPT)

EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments

GlobeNewsWire • 05/03/23

EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023

GlobeNewsWire • 04/26/23

Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?

Zacks Investment Research • 04/20/23

EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD

GlobeNewsWire • 03/27/23

EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

GlobeNewsWire • 03/20/23

Down -32.42% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)

Zacks Investment Research • 03/09/23

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2022 Earnings Call Transcript

Seeking Alpha • 03/02/23

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research • 03/02/23

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments

GlobeNewsWire • 03/02/23

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023

GlobeNewsWire • 02/23/23

EyePoint Investor Alert

Newsfile Corp • 02/12/23

EyePoint Shareholder Action Reminder

Newsfile Corp • 02/05/23

EYEPOINT SHAREHOLDER ACTION REMINDER

PRNewsWire • 01/28/23

EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

GlobeNewsWire • 01/23/23

EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options

PRNewsWire • 01/22/23

EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

GlobeNewsWire • 01/05/23

EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D.

GlobeNewsWire • 01/04/23

EYEPOINT INVESTOR ALERT

PRNewsWire • 12/25/22

5 Penny Stocks To Buy According To Analysts, Targets Up To 992%

PennyStocks • 11/14/22

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2022 Earnings Call Transcript

Seeking Alpha • 11/02/22

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates

Zacks Investment Research • 11/02/22

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

GlobeNewsWire • 11/02/22

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

GlobeNewsWire • 10/26/22

Eyepoint Investor Alert

Newsfile Corp • 10/19/22

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

GlobeNewsWire • 09/29/22